{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:00:02Z","timestamp":1789722002599,"version":"4.0.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300762"],"award-info":[{"award-number":["82300762"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) that has been approved by the FDA for patients with locally advanced or metastatic urothelial carcinoma (UC). This study presents a comprehensive pharmacovigilance analysis of the post-marketing safety profile of EV in the real-world based on the US Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse event (AE) reports regarding EV between January 2020 and December 2023 were obtained from the FAERS database. The standardized MedDRA query (SMQ) narrow search AEs on the preferred term (PT) level were used. Disproportionality analysis was performed to identify the AE signals for EV with the reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2,216 reports regarding EV were included in the present study. SMQ analysis results indicated that a stronger strength signal was found in severe cutaneous adverse reactions, retroperitoneal fibrosis, and peripheral neuropathy. A total of 116 significant disproportionality PTs referring to 14 system organ classes (SOCs) were retained by disproportionality analysis, with 49 PTs not listed on the EV drug label. Frequently reported EV-related AEs included rash, peripheral neuropathy, decreased appetite, alopecia, and pruritus. The time to onset of the majority of EV-related AEs was within 30 days (66.05%), with only 0.73% events occurring after 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The disproportionality analysis highlights that dermatologic toxicity and peripheral neuropathy were the major AEs induced by EV. The potential AEs not listed on the drug label were mainly related to gastrointestinal, hepatic, and pulmonary events. Further research is needed to confirm and explore the EV-related AEs in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1397692","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T04:34:58Z","timestamp":1724128498000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database"],"prefix":"10.3389","volume":"15","author":[{"given":"Mingming","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengda","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020960402","article-title":"Enfortumab vedotin-ejfv: A first-in-class anti-nectin-4 antibody-drug conjugate for the management of urothelial carcinoma","volume":"55","author":"Halford","year":"2021","journal-title":"Ann Pharmacother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated european association of urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN guidelines\u00ae Insights: bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00606-5","article-title":"Antibody-drug conjugates in the treatment of urothelial cancer","volume":"37","author":"Singh","year":"2023","journal-title":"BioDrugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.07.006","article-title":"Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review","volume":"40","author":"Padua","year":"2022","journal-title":"Urol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01360-1","article-title":"Nectin-4: a tumor cell target and status of inhibitor development","volume":"25","author":"Bouleftour","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2147\/cmar.S418009","article-title":"Current and emerging treatments for urothelial carcinoma: A focus on enfortumab vedotin","volume":"15","author":"Shafique","year":"2023","journal-title":"Cancer Manag Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.01.032","article-title":"Health-related quality of life of patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin after platinum and PD-1\/PD-L1 inhibitor therapy: results from cohort 1 of the phase 2 EV-201 clinical trial","volume":"81","author":"McGregor","year":"2022","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2212201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5165","article-title":"Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma","volume":"12","author":"Matsubara","year":"2023","journal-title":"Cancer Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"E424","DOI":"10.5489\/cuaj.7367","article-title":"Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text","volume":"15","author":"Bhindi","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistic","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-019-01241-7","article-title":"Clinical overview of enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma","volume":"80","author":"Hanna","year":"2020","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.5.929","article-title":"The role of data mining in pharmacovigilance","volume":"4","author":"Hauben","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000001562","article-title":"Assessing taxane-associated adverse events using the FDA adverse event reporting system database","volume":"134","author":"Lao","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02044","article-title":"EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.067","article-title":"Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma","volume":"85","author":"Hirotsu","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0328","article-title":"Enfortumab vedotin in the treatment of urothelial cancers and beyond","volume":"18","author":"Wong","year":"2022","journal-title":"Future Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3450","article-title":"Postmarketing cases of enfortumab vedotin-associated skin reactions reported as stevens-johnson syndrome or toxic epidermal necrolysis","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.801199","article-title":"Cutaneous toxicity associated with enfortumab vedotin: A real-word study leveraging U.S. Food and drug administration adverse event reporting system","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1188\/21.Cjon.E1-e9","article-title":"Enfortumab vedotin: nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma","volume":"25","author":"Pace","year":"2021","journal-title":"Clin J Oncol Nurs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030744","article-title":"Antibody-drug conjugate using ionized cys-linker-MMAE as the potent payload shows optimal therapeutic safety","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ceb.2007.09.007","article-title":"The roles of nectins in cell adhesions: cooperation with other cell adhesion molecules and growth factor receptors","volume":"19","author":"Sakisaka","year":"2007","journal-title":"Curr Opin Cell Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2457","article-title":"Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation","volume":"9","author":"Takai","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.Ccr-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2277801","article-title":"A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system","volume":"23","author":"Sun","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01673-y","article-title":"Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system","volume":"46","author":"Lin","year":"2024","journal-title":"Int J Clin Pharm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1397692\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T04:35:01Z","timestamp":1724128501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1397692\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2024.1397692"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1397692","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"article-number":"1397692"}}